Back to News
Market Impact: 0.25
City Therapeutics Raises $200 Million in Upsized US IPO
Source: Bloomberg
IPOs & SPACsHealthcare & Biotech
City Therapeutics, an early-stage RNAi-based drug developer, raised $200 million in its U.S. IPO, priced at the midpoint of its marketed range.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- Yields continue to rattle investors. These sectors are most at risk if rates stay elevated
- After years of U.S. export bans, China plans its own: 40 AI, chip and solar technologies could be restricted
- Anthropic signs first Canada data centre lease as EverWind plans C$10B investment
- CoreWeave, Nscale Put Neocloud Economics in Focus
- MapLight Therapeutics CMO Erin Foff sells $124,068 in stock
- William Blair initiates Revolution stock with outperform on RAS franchise